Comparison

Anti-Human von Willebrand factor (vWF) (Caplacizumab) - 25 mg

Item no. LEIN-V30-25mg
Manufacturer Leinco Technologies
Amount 25 mg
Quantity options 1 mg 100 mg 25 mg 50 mg 5 mg
Category
Type Antibody Monoclonal
Applications ELISA, FA, other
Clone ALX-0081
Specific against other
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Applications
B, ELISA, FA
Manufacturer - Category
All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies
Manufacturer - Targets
von Willebrand Factor (vWF)
Shipping Temperature
2 - 8°C Wet Ice
Storage Conditions
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Product Description
von Willebrand factor (vWF) is a plasma glycoprotein involved in clot formation via theadhesion of platelets to subendothelial collagen1, 2. A severe deficiency of the vWF-cleavingmetalloproteinase ADAMTS13 leads to acquired thrombotic thrombocytopenic purpura (aTTP), a rare autoimmune blood clotting disorder caused by anti-ADAMTS13 autoantibodies2. ReducedADAMTS13 activity leads to the accumulation of ultra-large vWF multimers in the blood. Thesebind to platelets, leading to the formation of platelet-rich microthrombi in the microvasculature.These microvascular occlusions ultimately lead to thrombocytopenia, hemolytic anemia, tissueischemia, and organ dysfunction. ADAMTS13 activity can be normalized via a combination ofplasma exchange, immunosuppression, and immunotherapy. ALX-0081 (Caplacizumab) was developed as a treatment for thrombosis in high-risk patientswith acute coronary syndrome, including treatment of aTTP2. Caplacizumab was generated as asingle-domain antibody fragment and consists of two identical, humanized building blockslinked by a 3-alanine linker2, 3. The precursor of Caplacizumab was isolated from a llamaimmunized with the recombinant A1 domain of vWF, humanized, and used to form amonovalent vWF-binding Nanobody (PMP12A2h1)3. The bivalent form was subsequentlyproduced in Escherichia coli using a secretory system. Caplacizumab inhibits the interaction between vWF and the platelet glycoprotein Ib-IX-Vreceptor, preventing platelet adhesion at high shear rates like those observed in stenosed arteries2, 3. Administration of caplacizumab in patients leads to rapid suppression of ristocetin cofactor, abiomarker for vWF activity, as well as reductions in VWF antigen and factor VIII.
Manufacturer - Research Area
Autoimmune, Biosimilars, Cardiovascular Disease, Immunology, Blood Coagulation
Concentration
≥ 5.0 mg/ml
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Antigen Distribution
vWF is found in blood plasma, the subendothelial matrix, storage granulesof endothelial cells, platelets, and megakaryocytes. vWF can also be found in macrophages, where it is bound and endocytosed during clearance.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close